What is it about?
We identified unexpected off-target cells, termed PMSCs (proliferative MSC- and SMC-like cells), that emerged after the implantation of iPSC-derived pancreatic islet cells. Additionally, we developed an in vitro detection system and effective removal methods for PMSCs.
Featured Image
Photo by Kevin Kandlbinder on Unsplash
Why is it important?
The unrestricted capacity of human induced pluripotent stem cells (iPSCs) to proliferate and differentiate is a major advantage for the development of cell-based therapies. However, this advantage is accompanied by a risk of off-target cell proliferation and tumorigenesis. Therefore, minimizing the risk of off-target cell contamination is imperative for the safe use of iPSC-derived products.
Perspectives
I hope that this research will be a starting point to increase the safety of pluripotent stem cell-derived cell therapy products. Beyond that, I also hope that cell therapy will become more commonplace.
Hideyuki Hiyoshi
Takeda Pharmaceutical Company Limited
Read the Original
This page is a summary of: Identification and removal of unexpected proliferative off-target cells emerging after iPSC-derived pancreatic islet cell implantation, Proceedings of the National Academy of Sciences, April 2024, Proceedings of the National Academy of Sciences,
DOI: 10.1073/pnas.2320883121.
You can read the full text:
Contributors
The following have contributed to this page
